Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: Analysis of American college of Rheumatology criteria scores 20, 50, and 70

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 429-464

  Orme, Michelle E ^a   MacGilchrist, Katherine S ^b   Mitchell, Stephen ^b   Spurden, Dean ^c   Bird, Alex ^c  

^a Icera Consulting   (United Kingdom)

^b Decision Resources Group   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

bDMARD; Comparative effectiveness; Etanercept; Network meta analysis; Rheumatoid arthritis; Systematic review

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84872238508     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S36707     Document Type: Article

References (89)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285): 903-911.
2. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford). 2002;41(7):793-800.
3. Alishiri GH, Bayat N, Salimzadeh A, et al. Health-related quality of life and disease activity in rheumatoid arthritis. J Res Med Sci. 2011;16(7): 897-903.
4. Smith HS, Smith AR, Seidner P. Painful rheumatoid arthritis. Pain Physician. 2011;14(5):E427-E458.
5. Strand V, Sharp V, Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012;71(7):1143-1150.
6. Boonen A, Mau W. The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S112-S117.
7. Foster W, Carruthers D, Lip GY, Blann AD. Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-Inflammatory treatment. J Thromb Thrombolysis. 2010;29(4):437-442.
8. Thwaites C, Finney A. Rheumatoid arthritis. 2: Exploring treatment options to achieve early control and remission. Nurs Times. 2010; 106(10):18-20.
9. National Institute for Health and Clinical Excellence. Rheumatoid arthritis (CG79): full guideline. London, UK: NICE; 2009. Available from: http://guidance.nice.org.uk/CG79/Guidance. Accessed October 30, 2012.
10. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137-145.
11. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6): 964-975.
12. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infiximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10(42):iii-iv, xi-xiii, 1-229.
13. Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2010;37(2):234-245.
14. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. J Rheumatol. 2006; 33(6):1075-1081.
15. Blumenauer B, Judd M, Cranney A, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2003(4):CD004525.
16. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37(6):1096-1104.
17. Blumenauer B, Judd M, Wells G, et al. Infiximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2002(3):CD003785.
18. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J. 2010; 128(5):309-310.
19. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011;38(1):10-20.
20. Canadian Agency for Drugs and Technologies in Health. Clinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid Arthritis. Ottawa, ON: CADTH; 2010. Available from: http://www.cadth.ca/media/pdf/TR_RA_Clinical_and_Economic_Overview_e.pdf. Accessed May 2, 2012.
21. ClinicalTrials.gov [homepage on the Internet]. US National Institutes of Health. Available from: http://clinicaltrials.gov. Accessed April 11, 2012.
22. National Institute for Health and Clinical Excellence. Appendix D: Methodology checklist - randomised controlled trials. London, UK: NICE; 2009. Available from: http://www.nice.org.uk/media/633/21/The_guidelines_manual_2009_-_Appendix_D_Methodology_checklist_-_randomised_controlled_trials.pdf. Accessed October 30, 2012.
23. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000; 320(7249):1574-1577.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109): 629-634.
25. Higgins JPT, Deeks JJ, Altman DG, editors. Intention-to-treat issues for dichotomous data. In: Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons; 2009.
26. Harris R, Bradburn M, Deeks JJ, Harbord R, Altman DG, Sterne J. Metan: Fixed- and random-effects meta-analysis. Stata J. 2008;8(1):3-28.
27. [No authors listed]. Software updates (Metan). Stata J. 2008;8(4): 594.
28. Bucher HC, Guyatt GH, Griffth LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683-691.
29. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9(26):1-134, iii-iv.
30. Caldwell DM, Ades AE, Higgins J P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897-900.
31. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics. 2008;26(9):753-767.
32. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105-3124.
33. The BUGS project, MRC Biostatistics Unit. Bayesian Inference Using Gibbs Sampling (BUGS) project. WinBUGS 1.4.3. Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml. Accessed October 30, 2012.
34. Spiegelhalter DJ, Abrams KR, Myles J P. Bayesian Approaches to Clinical Trials and Health Care Evaluation. Chichester, UK: John Wiley & Sons; 2004.
35. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001;10(4):277-303.
36. The BUGS Project. Winbugs 1.4 beta version. New examples for WinBUGS. Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/examples.shtml. Accessed October 30, 2012.
37. Dias S, Welton N, Sutton A, Ades AE. NICE DSU technical support document 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomised controlled trials. London, UK: NICE; 2011. Available from: http://www.nicedsu.org.uk/Evidence-Synthesis-TSD-series(2391675).htm
38. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 5: evidence synthesis in the baseline natural history model. London, UK: NICE; 2011. Available from: http://www.nicedsu.org.uk/Evidence-Synthesis-TSD-series(2391675).htm
39. Hasselblad V. Meta-analysis of multitreatment studies. Med Decis Making. 1998;18(1):37-43.
40. Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Anal. 2006;1(3):515-533.
41. Higgins JPT, Deeks JJ, Altman DG, editors. Special topics in statistics: rare events. Studies with zero-cell counts. In: Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons; 2009.
42. Combe B, Codreanu C, Fiocco U, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis. 2006;65(10):1357-1362.
43. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-2980.
44. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus meth-otrexate is Significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319-3329.
45. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of cer-tolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009; 68(6):797-804.
46. Kameda H, Ueki Y, Saito K, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol. 2010;20(6):531-538.
47. van Riel PL, Taggart AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis. 2006;65(11):1478-1483.
48. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50(5):1412-1419.
49. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349(20):1907-1915.
50. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week Efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010;62(4):917-928.
51. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-2829.
52. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-997.
53. Zhang FC, Hou Y, Huang F, et al. Infiximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. Int J Rheum Dis. 2006;9(2):127-130.
54. Klareskog L, van der Heijde D, de Jager J P, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-681.
55. Pfizer. TEMPO CSR 36848. 24-week data, Ta ble 9.4.2.2A. Data on fle.
56. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med. 2006;166(12):1269-1275.
57. The BUGS Project. DIC: deviance information criterion. Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/dicpage.shtml. Accessed October 30, 2012.
58. Abe T, Takeuchi T, Miyasaka N, et al. A multicenter, double-blind, randomized, placebo controlled trial of infiximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol. 2006;33(1):37-44.
59. Chen DY, Chou SJ, Hsieh T Y, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc. 2009;108(4):310-319.
60. Durez P, Nzeusseu Toukap A, Lauwerys BR, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infiximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis. 2004;63(9):1069-1074.
61. Emery P, Deodhar A, Rigby W F, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Ritux-imab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69(9):1629-1635.
62. Huang F, Zhang FC, Bao CD, et al. Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study. Zhonghua Nei Ke Za Zhi. 2009;48(11):916-921. Chinese.
63. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(4):964-975.
64. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(2):353-363.
65. Kim H Y, Lee SK, Song Y W, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. Int J Rheum Dis. 2007;10(1):9-16.
66. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-876.
67. Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M Jr. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc. 2004;103(8):618-623.
68. Maini R, St Clair E W, Breedveld F, et al. Infiximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrex-ate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932-1939.
69. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abata-cept or infiximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096-1103.
70. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253-259.
71. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant metho-trexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45.
72. Westhovens R, Yocum D, Han J, et al. The safety of infiximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54(4):1075-1086.
73. Johnsen AK, Schiff MH, Mease PJ, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol. 2006;33(4):659-664.
74. Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18(3):252-262.
75. Moreland LW, Schiff MH, Baumgartner S W, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130(6):478-486.
76. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12-19.
77. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multi-center, double-blind, placebo-controlled trial. Arthritis Rheum. 2004; 50(6):1761-1769.
78. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508-516.
79. van de Putte LBA, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor a monoclonal antibody adali-mumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003;62(12):1168-1177.
80. Moreland LW, Baumgartner S W, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337(3): 141-147.
81. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581.
82. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite metho-trexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009; 68(6):789-796.
83. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheu-matic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68(6): 805-811.
84. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580-1584.
85. Bergman GJD, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen J P. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010;39(6): 425-441.
86. National Institute for Health and Clinical Excellence. Rheumatoid arthritis - adalimumab, etanercept and infiximab (TA130). London, UK: NICE; 2007. Available from: http://guidance.nice.org.uk/TA130. Accessed October 30, 2012.
87. National Institute for Health and Clinical Excellence. Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225). London, UK: NICE; 2011. Available from: http://guidance.nice.org.uk/TA225. Accessed October 30, 2012.
88. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak P P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-279.
89. Thorlund K, Druyts E, Aviña-Zubieta JA, Wu P, Mills E. Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis. Epub October 20, 2012.